VALERE [Latin, pr. Vah-lèh-re, v. intr.]: To be brave, to be healthy, to be good at something, to be valuable.

Valere is the new independent financial advisory house focused on healthcare.

We create value, we are driven by values.

01 – WHAT DRIVES US

Our ambition

To be the trusted advisor (for companies and financial sponsors, alike) on corporate finance transactions involving Italian healthcare companies. We love helping companies use finance as a tool to achieve their strategic goals as well as the objectives of their shareholders.

Our values

We started this professional journey to fulfil our quest for a meaning in our undertakings and to contribute to a fresh approach to our job: we have a true passion for what we do, we are relentlessly curious and we believe in long-term trust built over integrity and competence. Our values are what drives and defines us.

02 – WHAT WE DO

Our scope: all subsectors of healthcare: Pharma / Biotech, MedTech, Healthcare Services (both B2B and B2C). While one leg of our transactions is typically in Italy, we have a global horizon and reach. We typically focus on transactions with a deal value of €20-100m, but we are flexible, competent and effective also outside this size range.

Our expertise: M&A advisory (acquisitions, disposals, mergers), IPO advisory, debt advisory, strategic assessments, business planning, valuation.

Acquisitions

On acquisitions, we typically support in the approach to targets (whether pre-identified, or to be identified via a scouting process), in the assessment of the potential strategic fit with our client and of the appropriate value and in the execution support all the way to final negotiations and closing.

Disposals

On disposals, we normally help select the appropriate time to market, we help define the transaction perimeter and the transaction type (majority vs. minority vs. capital increase), we support in the identification of potential buyers and in the definition of the most suitable disposal process (broad auction vs. limited auction vs. one-to-one vs. dual track); we dedicate significant time and effort in preparing thoughtfully and presenting at best the equity story (“financial storytelling”), driving the preparation of adequate marketing materials (teasers, information memoranda, etc.); we carefully coach management teams on delivering effective presentations; we provide execution support on business planning, valuation, project management (including the coordination of a carefully prepared due diligence process) and negotiations up to closing.

IPO advisory & debt advisory

On IPO advisory and debt advisory, we help analyze the optimal financial structure, transaction perimeter and time to market, we support in designing the most attractive equity story / investment thesis, we create support for compelling valuation / transaction terms and we drive execution, coordinating complex processes.

Strategic assessments

On strategic assessments, we help analyze the positioning of a company to identify the best strategic and financing options based on the client’s objectives and needs, on market dynamics and on competitive landscape; we identify, free from conflicts of interest, the most suitable avenues and we drive their execution.

Business planning & valuations

On business planning and valuations, we leverage off our solid financial skills and deep understanding of sector drivers and dynamics to draft (or, as the case may be, review) complex and solid business plans supporting a valuation exercise; where requested, we provide fairness opinions in the context of transactions.

03 – WHAT MAKES US DIFFERENT

Our uniqueness

We offer our clients not only a deep sector knowledge and a broad access to investment opportunities, but also a boutique approach, with significant senior time dedicated to projects, delivering a tailor-made, thoughtful, expert, unbiased advice. We strongly believe in the alignment of interests between us and our clients, as reflected by our fee structures. Reputation is our most valuable asset, which was built over years of serious work alongside our clients, always having their best interest as our only objective. And being entrepreneurs ourselves, we speak the same language as our clients.

Our relationships

We have access to virtually all Italian healthcare companies, ranging from large cap to small cap and across subsectors; we have relationships with most of the financial sponsors investing in Italy, from large buy-out Private Equity funds to Venture Capital firms.

04 – WHO WE ARE

Founded by Fabrizio de Simone, Valere can rely on a broad network of professionals, both in Italy and internationally. Our “open organization” approach delivers top-notch results to our clients, as we involve the best team, with relevant expertise and network, on every situation.

Background

Fabrizio de Simone, the founder of Valere, has 20+ years’ experience in corporate finance, the last 7 of which with an exclusive focus on healthcare as the Italian Life Sciences sector leader at EY. He started his career in the investment banking division at Citi (10 years between London, New York, Sydney and Milan), then was the co-founder of an Italian M&A boutique; he was finally part of the team that relaunched the Italian M&A practice at EY, before taking the leadership for the Life Sciences sector. He holds a degree with honours in Business Law from the Bocconi University and has attended a number of executive programs, including at the Wharton Business School and at the Harvard Business School. He has been trainer in various courses and speaker at many events, as well as and author of a number of publications. He speaks four languages and is passionate about innovation, leadership, travelling, art and design. More details on linkedin.com/in/fabriziodesimone

Our partnerships

We have partnerships with high-profile international firms, who provide (as appropriate and requested) additional services that are synergic to our corporate finance offering, including strategic consulting, operational support, financial, business and tax due diligence, legal and tax advice.

05 – TRACK RECORD

We have executed more than 100 transactions, mostly cross-border, with a cumulated value exceeding $25 billion, spanning from large deals to mid-cap transactions to start-up fundraising.

Advisor on the acquisition of Sochim International

Undisclosed amount

2024

Valuation

2024

Strategic assessment

2023

Market analysis

2023

Strategic assessment

2023

Market analysis

2022

Strategic assessment

2022

Business planning and valuation

2022

Strategic assessment and business planning

2021

Valuation of a portfolio of pharmaceutical products

2021

Advisor to AB Medica on the disposal of Officine Ortopediche Rizzoli to Barbieri

Undisclosed amount

2024

Advisor to the shareholders of TFS on the disposal to Filtrading

Undisclosed amount

2023

Advisor on the acquisition of Evamed

Undisclosed amount

2023

Advisor on the acquisition of OmniaMedica

Undisclosed amount

2019

Advisor to the shareholders of MDM on the disposal to Neopharmed Gentili

Undisclosed amount

2019

Advisor on the merger with Innova Italy 1 (SPAC)

€ 240 million

2018

Advisor on the acquisition of Fleming Research

Undisclosed amount

2017

Advisor on the acquisition of Delta Medica

Undisclosed amount

2017

Advisor on the acquisition of Italchimici

€ 130 million

2016

Advisor to the shareholders of Stilo on the disposal to Simpson

Undisclosed amount

2015

Advisor to Bridgepoint on the disposal of CFP Flexible Packaging to Domo

Undisclosed amount

2014

Advisor on the acquisition of Ermo (listed in France)

€ 25 million

2014

Advisor to Progressio SGR on the sale of JAL Group to Franco Uzzeni

Undisclosed amount

2014

Advisor to the shareholders of Industrie CBI on the disposal to Nicotra-Gebhardt

Undisclosed amount

2013

Advisor to Faberstone on the sale of Carlo Erba Reagenti to Dasit Group

Undisclosed amount

2013

Advisor to Euticals on the acquisition of Archimica

€ 65 million

2011

Advisor on the disposal of a hydroelectric power station

€ 10 million

2010

Advisor on the disposal of 61 stores to Megagest

Undisclosed amount

2010

Advisor on the disposal of four hypermarkets to Coop

Undisclosed amount

2009

Advisor to Cinven on the acquisition of Avio

€ 2,570 million

2006

Advisor to the Board of Directors of G-Tech on the acquisition by Lottomatica

US$ 4.8 billion

2006

Advisor on the acquisition of a 70% stake in Lucchini (capital increase + buy-out of minorities)

€ 511 million

2005

Advisor on the disposal of Etinera

€ 590 million

2004

Advisor on the tender offer on Polfa Kutno

€ 31 million

2004

Advisor to Quad-C on the sale of Util / CTD to Investitori Associati

Undisclosed amount

2003

Advisor on the acquisition of ETI

€ 2,325 million

2003

Advisor on the acquisition of Ausimont from Montedison

€ 1,300 million

2002

Advisor on the disposal of Magneti Marelli’s Electronic division to Mekfin

€ 70 million

2002

Advisor on the disposal of IM.SER to Beni Stabili and Lehman Brothers

€ 1.8 billion

2000

Advisor on the sale of a 26.6% stake in Wind to Enel and France Telecom

€ 2.7 billion

2000

Advisor on the sale of Almare

€ 69 million

2000

Private placement

Undisclosed amount

2021

Private placement (seed capital)

€ 1 million

2020

Private placement of Tuniverse LLC

US$ 30 million

2008

Placement agent in the AEO

€ 72 million

2006

Joint bookrunner and joint global coordinator in the IPO

€ 315 million

2006

Placement agent in the AEO

€ 51 million

2004

Joint Lead Underwriter in the Rights Offering

€ 544 million

2003

Joint Bookrunner in the IPO

€ 2,202 million

2001

Private placement of Arabia Online

US$ 12 million

2001

Secondary Equity Offering

€1.6 billion

1999

Senior loan and private placement

€ 25 million

2016

Minibond Issuance

€ 2 million

2015

Leveraged recapitalization

US$ 66 million

2011

Renegotiation of a term loan and other credit facilities

€ 10 million

2010

Senior loan and factoring of receivables

Undisclosed amount

2010

Syndicated loan

€ 300 million

2005

Republic of Hungary – Global Bond Offering (SEC-Registered)

US$ 750 million

1999

National Bank of Hungary – Eurobond Offering

US$ 350 million

1998

Business planning and valuation

2020

Strategic assessment

2019

Strategic assessment

2018

Strategic assessment

2018

Strategic assessment

2018

Business planning

2017

Strategic assessment

2016

Business planning and valuation

2015

Business planning

2015

Business planning

2014

Business planning

2012

Business planning

2012

Business planning

2012

Business planning

2011

Business planning on supermarkets in Sicily

2011

Business planning

2009

Business planning

2009

Strategic assessment

2007

Fairness opinion

1999

Fairness opinion

1999

06 – NEWS

December 17, 2024 – We are pleased to announce that we have been exclusive financial advisors to Naturacare on the acquisition of Sochim International. Naturacare, backed by Dentressangle Capital, makes with this transaction another important step in the creation of a Pan-European leading CDMO in the dietary supplements sector, with c. €100m in revenues and c. 350 employees working in 5 plants across 4 countries. The Eigenmann family will remain involved via a reinvestment in Naturacare and an executive leadership role. Read more…

February 14, 2024 – Honored and proud to have assisted Ab Medica on this important transaction, which gives Officine Ortopediche Rizzoli the opportunity for another chapter in its 100+ years history of excellence in the Italian orthopaedic sector. Read more…

September 7, 2023 – Pleased to have assisted Apposite and 1MED on the acquisition of Evamed: it underpins 1MED’s strategy towards the creation of a pan-European CRO focused on medical devices. Read more…

CONTACT US

    Valere Advisory srl
    Milan | Italy
    VAT / FC 13530130965
    REA Number: MI – 2728850

    Subject to management and coordination by Valere Holding srl, single-quotaholder limited liability company (P. IVA IT-13509740968)

    Privacy Policy

    Valere and the Valere logo are a registered trademark